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NanoLuc Luciferase – A
Multifunctional Tool for High
Throughput Antibody Screening
Nicolas Boute1*, Peter Lowe1, Sven Berger1, Martine Malissard2, Alain Robert1 and
Michael Tesar1
1 Molecular and Cellular Biology Unit, Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre,
Saint-Julien-en-Genevois, France, 2 Biochemistry Department, Institut de Recherche Pierre Fabre, Centre d’Immunologie
Pierre Fabre, Saint-Julien-en Genevois, France
Based on the recent development of NanoLuc luciferase (Nluc), a small (19 kDa), highly
stable, ATP independent, bioluminescent protein, an extremely robust and ultra high
sensitivity screening system has been developed whereby primary hits of therapeutic
antibodies and antibody fragments could be characterized and quantified without
purification. This system is very versatile allowing cellular and solid phase ELISA but
also homogeneous BRET based screening assays, relative affinity determinations with
competition ELISA and direct Western blotting. The new Nluc protein fusion represents
a “swiss army knife solution” for today and future high throughput antibody drug
screenings.
Keywords: NanoLuc R© luciferase, bioluminescence resonance energy transfer (BRET), homogeneous assay,
affinity determination, expression analysis, Western blot, library screening, phage display
INTRODUCTION
Since the birth of recombinant protein technology a vast range of different protein fusion and
protein tag systems (Terpe, 2003; Waugh, 2005) have been developed for screening and/or
purification of biologics from various different libraries and expression hosts. These proved
particularly useful for the detection of polypeptides that lack a constant region such as scFv (Bird
et al., 1988). Concurrently automated high throughput screening platforms and miniaturization
have constantly evolved (chip technology, fluidic systems) such that tag and reporter systems must
cope with the required sensitivity, speed and economy on one side and promote early screening
for favorable functionality and developability parameters (during early screening paths) on the
other. To date, there is no tag or reporter protein that fulfills all parameters all at once. In most
cases tags are combined in order to fulfill the basic requirements such as detection (Ullmann,
1984; Griep et al., 1999; Dammeyer et al., 2013) and purification (di Guan et al., 1988; Smith
and Johnson, 1988; Smith et al., 1988; Cronan, 1990; Einhauer and Jungbauer, 2001; Schmidt and
Skerra, 2007; Malpiedi et al., 2013). Therefore, the selection of such reporters and/or tags must be
taken carefully as they are decisive for the selection and finally the quality of potential therapeutic
antibody candidates.
For high throughput screening, homogenous immunoassays are ideal due to the absence of
numerous incubation and washing steps. Due to signal-amplification the most sensitive reporter
systems appear to be enzymes. Alkaline phosphatase (Kerschbaumer et al., 1997; Griep et al., 1999;
Abbreviations: BRET, bioluminescence resonance energy transfer; Fluc, Firefly luciferase; GFP, green fluorescent protein;
Nluc, NanoLuc luciferase; Rluc, Renilla luciferase; scFv, single chain antibody fragment; SET, solution equilibrium titration;
YFP, yellow fluorescent protein.
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Liu et al., 2013), beta-galactosidase (Ullmann, 1984) and
Gaussia or Rluc (Venisnik et al., 2006; Han et al., 2013) have
been successfully fused genetically and employed in screenings
(Harper et al., 1997). However, those enzyme reporters increase
substantially the size of the studied protein and the valency of
the fusion construct. Alternatively, different fluorescent proteins
such as GFP and YFP have been successfully applied as reporters
(Cassimeris et al., 2013; Dammeyer et al., 2013) but still with a
compromise of lower sensitivity, lower solubility and/or higher
background of the fusion protein due to auto fluorescence.
Recently a novel luminescent protein, Nluc has been
developed by Promega. Engineered by directed evolution from
a deep-sea shrimp (Oplophorus gracilirostris) luciferase, the
enzyme was concomitantly optimized with the identification
of a novel substrate obtained by synthesis and screening of
coelenterazine analogs (Hall et al., 2012). The resulting Nluc
protein is a 19.1 kDa, monomeric, highly soluble and stable, ATP-
independent enzyme. The novel substrate, furimazine, produces
a glow type luminescence (half-life > 2 h) with a higher
specific activity than Rluc or Fluc (Hall et al., 2012). The high
luminescence intensity of Nluc, its high solubility and its small
size (19.1 kDa) compared to Rluc (36 kDa) or to Fluc (61 kDa)
indicate that Nluc could be a potent tool for in vitro protein–
protein interaction assays.
Based on these new and favorable characteristics, we
constructed several vectors that allow cloning of Nluc at the
C-terminus of a scFv or the heavy chain of a complete IgG
molecule. In parallel the assay conditions were optimized to
further increase sensitivity. Finally this new reporter system
was applied and tested by screening of scFv library pannings
after subcloning of polyclonal outputs into the new Nluc fusion
vector. The evaluation focused not only on its sensitivity and
its adaptability to high throughput screenings but also on
the following important first pass parameters that could be
analyzed in parallel without purification step: (i) antigen and/or
cell binding, (ii) productivity in procaryotic and eucaryotic
expression systems and finally, (iii) affinity ranking. In addition
the Nluc reporter showed its versatility in homogenous assay
set-ups, competition ELISAs and Western blots.
MATERIALS AND METHODS
Protein targets used in this work are tyrosine kinase receptor
family members (1–3) while target 4 is a nuclear protein.
Generation of Nluc scFv and Antibody
Fusions
The Nluc gene was amplified from vector pNL3.1 with
primers: nLucMluS ATGGAAGCTCGACTTCCAGCTTG
and nLucEcoAS CGCCAGAATGCGTTCGCACAGC using
Phusion R© High-Fidelity DNA polymerase (NEB), and the PCR
cycles, 98◦C × 30 s × 1, followed by 30 cycles of 98◦C × 5 s,
72◦C × 20 s, followed by a final extension step of 72◦C × 2 min.
The resulting PCR product was subcloned into the phage display
vector pPL101 replacing the gene III fusion protein. Nluc and
vector DNA were digested with Mlu I and Eco RI purified
and ligated with T4 DNA ligase. The ligation product was
transformed in to chemically competent Escherichia coli Top10
cells (Invitrogen) according to the manufacturer instructions.
The Nluc gene was genetically fused to the C-terminal
part of the constant domains of a human IgG1 by directed
ligation (Lebedenko et al., 1991). Constant domains
were amplified using the primers FwCH1-FcIgG1forNLuc
TTAGGTCTCGCTAGCCCCCAGCAGCAAGA and RevCH1-
FcIgG1forNLuc ATCTAGTCTGGTCTCTCGCCCTTGCCTG
GGGACAGGCTCAGGCTCTTCTGGGTGT and the Nluc gene
with the primers FwNLucFcIgG1fusion TTAGGTCTCTG
GCGGCGGCGGCTCCATGGTCTTCACACTCGAAGATTT
CGTTGGG and RevNLucFcIgG1fusion ATCTAGTCTGGT
CTCGGATCCTTACGCCAGAATGCGTTCGCACAGCC using
Phusion R© High-Fidelity DNA polymerase (NEB) following
the instructions of the manufacturer. Purified PCR product
were digested with BsaI-HF (NEB), ligated and cloned in the
mammalian expression vector pCEP.
Establishing Bioluminescence Assay
Purified NanoLuc (Promega), was distributed in a 96-well half-
area white microplate (Costar, CLS3693) to a final concentration
of 10 pmol/L in PBS; PBS, 0.1% BSA; 50% Nano-Glo assay
buffer (Promega, N112B) in PBS or 50% Nano-Glo assay buffer,
0.1% BSA with two different dilutions (1/100 and 1/400 final)
of furimazine (Nano-GloTM assay substrate, Promega, N113B).
After a short centrifugation (500 rpm, 1 min) to gather reagent
in the bottom of wells, luminescence was read (0.1 s/well,
without filter) on a microplate reader (Mithras LB940, Berthold
Technologies, Germany) after different incubation times at room
temperature.
Nluc Luminescence Titration
Purified Nluc and Nluc-fused antibodies were sequentially
diluted in PBS-BSA 0.1% solutions. Ten microliters of each
dilution were distributed in triplicates in a 96-well half area white
microplate. Ten µL of furimazine diluted 200 times in PBS, 0.1%
BSA were then added in each well. After a short centrifugation
(500 rpm, 1 min), luminescence was read (0.1 s/well with
or without a 530/25 nm filter) on a Berthold Mithras LB940
microplate reader.
ELISA on Recombinant Protein
Ninety six well Immulon 2HB ELISA plates were coated with
predetermined saturating concentrations of recombinant target
protein in PBS 100 µL/well overnight at 4◦C. The following day
plates were saturated with 2% milk powder in PBS.
Random clones from panning to each target antigen cloned
into pPL302 were inoculated in 100 µL 2× YT/Amp/0.1% Gluc
and incubated for at least 6 h at 30◦C with shaking. The scFv
expression was induced by adding IPTG to a final concentration
of 0.1 mmol/L and incubated overnight at 30◦C with shaking.
E. coli cells were lysed by adding an equal volume of 2×
BBS/lysozyme buffer (24.7 mg/mL boric acid, 18.7 mg/mL NaCl,
1.48 mg/mL EDTA, 2.5 mg/mL lysozyme, adjusted to pH 8.0 with
10 mol/L NaOH) and following a 30 min incubation at room
temperature were subsequently blocked with 1/5 culture volume
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of 12.5% milk powder, 0.05% Tween R© in PBS and were incubated
for a further 30 min at room temperature. The cultures were
then centrifuged for 5 min at 1800 g and 50 µL of supernatant
added to precoated and saturated ELISA plates. Between each
incubation step three washes with PBS, 0.05% Tween R© and three
washes with PBS were performed. The scFv binding was detected
by ELISA using the anti-pIII antibody pSKAN3 (Mobitech
GmbH, Göttingen) and an HRP-labeled anti-mouse IgG A-4416
(Sigma-Aldrich, Saint-Quentin Fallavier) detection antibody with
TMB ELISA peroxidase substrate (Interchim, Montlucon). Nluc
labeled scFv were cultured extracted and saturated in the same
manner, following a 1 h incubation step with target antigen, wells
were washed as previously described and 50 µL of Nano-Glo R©
substrate (Promega, N1120) diluted 1/400 in PBS was added.
Luminescence was measured with a Mithras LB 940 (Berthold
Technologies) with a read time of 0.1 s.
Cell ELISA
Wild type and target-over-expressing Chinese Hamster
Ovary (CHO) cells were seeded at 20000 cell/well in 96-
well white microplate (CulturPlate, PerkinElmer) and cultured
2 days in Dulbecco’s Modified Eagle’s Medium (DMEM)-F12
supplemented with 5% FBS. After culture medium removal,
cells were washed twice with phosphate-buffered saline (PBS).
Wells were then saturated with a PBS-gelatine 0.5% solution
5 h at room temperature. After washing, cells were incubated
with anti-target scFv-Nluc extracts or control 1 h at room
temperature. After three washes with PBS, 50 µL of Nano-GloTM
assay substrate (1/400 dilution in PBS, 0.1% BSA) was added and
luminescence was read (0.1 s/well, without filter) on a Berthold
Mithras LB940 microplate reader.
Alexa488 Labeling of Recombinant
Targets
Purified recombinant targets were labeled with Alexa Fluor 488
(Alex Fluor 488 carboxylic acid succinimidyl ester, Molecular
Probes, A20000). Briefly, the recombinant target solution was
first dialyzed overnight at 4◦C against 0.1 M sodium bicarbonate
pH 9.0 buffer. After dialysis, Alexa Fluor 488 (10 mg/ml in
DMF) was added (dye-to-protein ratio of 20/1, mol/mol) and
the mixture was incubated in the dark, 1 h at room temperature
under continuous mixing. The reaction was stopped by dialysis
overnight in the dark against phosphate buffer saline pH 7.4.
The mixture was dialyzed twice. The protein concentration was
determined by BCA assay. The labeled targets were further
characterized by SDS-PAGE electrophoresis on 4–12% gradient
gel under reducing and non-reducing conditions. The gel was
stained with Coomassie Blue. The A488 Fluor labeling was
assessed by reading the gel with Molecular Imager R© VersaDocTM
MP Imaging System (Biorad). Alexa488-labeled recombinant
targets were stored sterile at 4◦C, protected from light.
Homogenous BRET Assays
Two different configurations were used for homogenous BRET
assays. In the first configuration we used target-Fc domain
fusion proteins (1 µg/mL final) which were incubated with
anti-target or control scFv-Nluc with or without a (Fab’)2 anti-
hIgG-PE (phycoerythrin; Beckman Coulter, IM0550) diluted
1/1000 final in a white 96-well white microplate. After a 15 min
incubation at room temperature, furimazine was added in all
wells and BRET was immediately measured on a Berthold
Mithras LB940 microplate reader by light-emission acquisition
at 485 and 568 nm. In the second configuration, the BRET
ratio was measured by comparison of light emitted by wells
containing only anti-target or control scFv-Nluc versus wells
containing anti-target or control scFv-Nluc and the target
chemically labeled with Alexa488. In all configurations specific
BRET signal (net BRET) expressed in milliBRET Unit (mBU)
corresponds to the ratio of the light emitted by acceptors
[Alexa488 (530 nm) or PE (568 nm) over donor Nluc (480 nm)]
minus the same ratio measured on wells containing only the
donor multiplied by 1000 (Angers et al., 2000; Boute et al.,
2001).
Binding Competition ELISA
Wells of a 96 well white flat bottom polystyrene High
Bind microplate (Costar) were coated overnight at 4◦C with
recombinant target protein (0.2 µg/mL in PBS) followed by a
saturation step of at least 2 h at 37◦C with gelatine 0.5% in PBS.
NanoLuc fused antibody 1 nmol/L was then added in each well
simultaneously with various amounts of competitors or controls.
After 1 h incubation and three washing steps, 50 µL of Nano-
GloTM assay substrate (1/400 dilution in PBS/BSA 0.1%) was
added and luminescence read (0.1 s/well) on a Berthold Mithras
LB940 microplate reader.
Western Blot
Briefly, commercial recombinant His tagged target 2 and
Fc tagged target 3 extracellular domains (0.1 µg per lane)
were migrated heated, non-reduced, on 4–15% precast
polyacrylamide gel (Bio-Rad, Criterion TGX 567-1084)
according to manufacturer’s protocol. Proteins were then
transferred on nitrocellulose membranes using Trans-Blot R©
TurboTM Midi Nitrocellulose Transfer Packs (2.5 A, 25 V,
7 min). After a 1 h, room temperature saturation step in Tris
buffered saline, 0.05% Tween 20, 1% milk (TBS-T 1% milk),
membranes were incubated overnight at 4◦C with either a
naked or a Nluc-fused anti-target 2 antibody (1 µg/mL), a
1/50 diluted periplasmic extract of Nluc fused-anti-target
2 scFv or Nluc fused-anti-target 3 scFv. After three washes
in TBS-T, the membrane labeled with naked anti-target 3
antibody was incubated (1 h) with an anti-human kappa light
chain-HRP secondary antibody (1/10000 in TBS-T 1% milk;
Sigma, A7164). After three additional washes, the labeling
was revealed with ECL blotting substrate (Pierce, 32106) on
ECL film. In parallel, membranes labeled with Nluc fused
scFv or antibody were washed three times with TBS-T and
then revealed with furimazine (1/1000 in PBS, 0.1% BSA;
Nano-GloTM assay substrate, Promega, N113B) on ECL
film.
Software
Analyses were carried out with GraphPad Prism6.
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RESULTS
Strategy and Constructs
For the evaluation of the Nluc Luciferase (Nluc) as a versatile
reporter system five different antibodies have been used as either
scFv Nluc fusions or IgG Nluc fusions or both. All five antibodies
were directed against different antigens. The antibodies were
applied in different experimental settings for proof-of-concept
and to demonstrate the versatility of the Nluc as a reporter
system.
Initially experimental conditions were optimized in order to
obtain the highest sensitivity from the system. In a second step
the Nluc reporter system was challenged in standard antibody
screening procedures including (a) high throughput primary
screens that could be easily adapted to automation (e.g., ELISA
and homogeneous assay), (b) antibody competition set-up for
epitope grouping or for the selection of optimized antibody
variants (e.g., humanizations or affinity maturations) and finally
c) the selection of antibodies that could be used in specific
applications (e.g., Western blot).
Optimization of Nluc Luciferase Assay
Conditions
Recently a kit to detect Nluc activity comprising the Nano-Glo R©
luciferase substrate (furimazine) and a lysis/reaction buffer has
been commercialized (Promega). However, to adapt Nluc for
antibody screening on protein antigens and whole cells the buffer
conditions for the Nluc needed to be optimized. Especially, the
presence of detergent in the reaction buffer as recommended by
the supplier is not applicable for real time experiments on live
cells. For the optimizations of assay conditions purified Nluc was
used. As a starting point Nluc (10 pmol/L) performance in PBS
showed a weak luminescence intensity and a fast decay of the
signal compared to the signal obtained with the commercially
supplied buffer (half-life of 17 min vs. 80 min; Figure 1).
We found that through the addition of 0.1% BSA the Nluc
luminescence signal strongly increased and even exceeded the
signal of the commercial buffer by up to 25 fold. In addition the
half-life increased from 17 to 60 min but still did not match that
obtained with the commercially supplied buffer conditions (60 vs.
80 min). The difference in half-life is not the result of furimazine
limitation since a similar half-life was obtained in PBS, 0.1% BSA
when the Nluc substrate was diluted 400 times instead of 100
times as recommended by the supplier. Moreover, the addition
of 0.1% BSA to Promega’s buffer conditions also greatly increased
Nluc luminescence (up to 10-fold) reaching about half of the
signal obtained for PBS supplemented with 0.1% BSA and an
extended half-life of 100 min. Based on those results all further
experiments were carried out in PBS supplemented with 0.1%
BSA.
Nluc scFv Fusions for High Throughput
Primary Screening
In order to demonstrate that Nluc can be used as a reporter
system and its small size (171 amino acids) neither compromises
efficient bacterial production nor the function of a fusion partner,
FIGURE 1 | Purified NanoLuc glow kinetic in different buffer
conditions. Luminescence signal of purified Nanoluc (10 pmol/L) was
measured at several time points in a 20 µL final volume of several buffer
conditions : PBS (circle), PBS, 0.1% BSA (square); 50% Nano-Glo assay
buffer (Promega, N112B), 50% PBS (triangle) or 50% Nano-Glo assay buffer
50% PBS, 0.1% BSA (diamond) with 1/100 (white) or 1/400 (black) furimazine
final dilution. Graphs of a representative experiment, each experimental point
was performed in triplicate, and bars correspond to standard deviation (SD).
a scFv format has been chosen in a first application. For that
purpose a Nluc expression vector was constructed which allowed
the C-terminal fusion of single scFv genes or scFv pools to
the N-terminus of the Nluc reporter gene via a 24 aa linker
sequence derived from Promega vector pNL3.1 (Figure 2A) For
direct comparison and calibration of hit rates the detection via
anti-pIII (Tesar et al., 1995; Beckmann et al., 1998; Mersmann
et al., 1998) and anti-Strep-tag R© II (Knappik and Brundiers,
2009) was used. Five distinct immune phage libraries generated
in-house were subjected to three rounds of a standard phage
panning on immobilized protein (Hoogenboom et al., 1998)
and analyzed for specific scFvs directly expressed from the
phagemid vector pPL101 via anti-pIII or, after subcloning into
the two different expression vectors pPL302 via Nluc or pPL303
(Figure 2A), via an anti-Strep Tag II (Knappik and Brundiers,
2009). Primary screenings of the five different panning outputs
were performed by ELISA with directly coated antigen and
single chain-containing periplasmic E. coli extracts. Expression
of scFv-Nluc was directly evaluated by measuring luminescence
of culture supernatants or periplasmic extracts (Table 1). Binding
ELISA was performed on purified antigen. An irrelevant antigen
was coated at a saturating concentration to serve as a negative
control for binding. The scFv Nluc fusion binding was directly
measured after the scFv binding step followed by three washes,
a secondary antibody was not required. As shown in Table 1
comparable numbers of positive ELISA wells (hits) were obtained
for all three detection systems and four different libraries except
for target 3 library, L1, which resulted in approximately 40%
lower hit-rate for the Nluc reporter system vector, possibly
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FIGURE 2 | (A) Antibody libraries were created by cloning of assembled VH and VL genes after restriction digest with Nco I and Mlu I into phagemid vector pPL101.
Cloned scFv were preceded by the pelB signal sequence and VH and VL genes were joined by a linker sequence (L1). The scFv was finally fused to the “short”(1)
M13 gene III (corresponding to amino acids 251–406). After panning, the enriched phagemid population was digested by Nco I and Mlu I and subcloned into the
expression vectors pPL302 and pPL303. Deduced amino acid sequences are shown for the most relevant fusion sites including linker sequences
L1(QLKSSGSGSESKST), L2(GGGGSMEARLPAWQSGTVGKAT), L3(GGGSCYKDDDDKGGGGS), as well as for the anti-gIII (ATDYGAAIDGF) and the Strep-tagTM
epitope (WSHPQFEK). (B) For the pIgG Nluc vector the NanoLuc gene was fused downstream to the heavy chain IgG1 CH3 gene domain including the linker
sequence L4. Deduced amino acid sequences at the fusion site are shown for the linker L4 (GKGGGGS) and three N- and C-terminal amino acids of NanoLuc
(MVF. . .[Nluc]. . .ILA). Genes for the heavy chain variable region, the constant regions and the signal peptide are depicted as VH, CH1-3 and S.
due to a bias in the sub cloning procedure. Hits for the Nluc
reporter system were in most cases 100-fold above background
and corresponding expression judged as positive for values above
10000 RLU. Despite the similarities of positive hit rate observed
with the different detection strategies, sequence analysis was not
performed at this stage and thus identified antibodies may not be
the same between methods.
Luminescence Measurement for
Estimation of Ab-Nluc or scFv-Nluc
Fusion Concentration
Due to the inherent difficulty to quantitate scFvs we chose
to validate the quantification of fusion proteins via Nluc with
complete antibodies for which alternative dosing strategies were
readily available. Four different monoclonal antibodies in the
IgG1 format were fused to Nluc (mAb-Nluc1 to 4) and compared
to the luminescence signal of purified Nluc. To this end a new
vector was designed and the Nluc gene fused to C-terminal end
of the CH3 domain via a flexible linker (Figure 2B). IgGs were
expressed in transiently transfected CHO EBNA cells, purified
and further characterized by SDS-PAGE and size exclusion
chromatography. All IgGs showed a monomeric fraction of
>95% and no instability of the heavy chain-Nluc fusion was
observed (data not shown). As expected (Hall et al., 2012; Zhang
et al., 2013), a strong linearity was observed between the Nluc
concentration and the luminescence signal (Figure 3). Non-
linearity can occur with high enzyme level (>10 fmol/well)
most likely due to lack of substrate or luminescence signal too
close of reader saturation limit. After calculating equimolar Nluc
concentrations for each of the IgG Nluc-fusion proteins results
can be superimposed to the corresponding concentrations of
purified Nluc. Moreover, the dynamic range can be adjusted by
the use of a filter to avoid saturation of the photomultiplier for
high Nluc concentrations even with a 0.1 s reading time. Without
the use of a filter, saturation of our reader was observed when
concentrations exceeded 4 fmol per well (i.e., 200 pmol/L in
20 µL), but with a 530 nm filter readings can be made in excess
of 10 fmol per well. However, for higher Nanoluc concentrations,
furimazine can become limiting and thus we would recommend
sample dilution.
NanoLuc Fusion Proteins in a
Homogeneous Assay
For high throughput screening, homogenous assays are the best
solution as they are faster, simpler, and well suited to automation.
BRET (Couturier and Deprez, 2012) allows the study of protein–
protein interactions by detection of the resonance energy transfer
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TABLE 1 | Primary screening of panning outputs by ELISA.
Hit Rate [%]a and Expression Check [%]b of Libraries (L1 – L5)
hhhhhhhhhhhhhhhDetection (vector):
Antigen (libraries)
Target 3 (L1) Target 1 (L2) Target 3 (L3) Target 4 (L4) Target 4 (L5)
Anti-pIIIa (pPL101) 71 92 13 90 90
Anti-strep tag IIa (pPL303) 69 83 11 87 91
Nluca (pPL302) 32 80 10 87 98
Expression checkb 93 100 98 nd nd
aDefinition of “Hit”: signal > 5-fold over background.
bDefinition of Expression: >1.0E+04 RLU; only measured for scFvs expressed from pPL302.
nd, not determined.
FIGURE 3 | Comparison of luminescence intensity of purified Nluc
(circles) and two representatives of the four Nluc fused antibodies
(squares and diamonds) read without filter (filled) or with a 530 nm
filter (empty). Antibody concentrations are corrected in equivalent Nluc as
each antibody is linked to two Nluc. Each experimental point represents the
means of three independent experiments made in triplicates, bars correspond
to SD.
between a bioluminescent protein such as a luciferase and a
compatible fluorescent acceptor coupled or fused to proteins of
interest (Xu et al., 1999; Angers et al., 2000). Thus the binding of
a scFv-Nluc to its target could be detected if the target is directly
or indirectly labeled with a convenient fluorescent acceptor. The
Nluc emission spectrum shows a maximum emission at 460 nm
(Hall et al., 2012) which is compatible with the excitation profiles
of various fluorophores such as Alexa-Fluor-488, phycoerythrin
or YFP.
In order to set up the homogeneous assay, labeling conditions
were tested with the extracellular domain of target 3 or its Fc-
fusion derivative. The target 3 antigen was either directly coupled
to Alexa-Fluor-488 (Figure 4A) or, in case of the Fc-fusion
derivative, indirectly by an anti-human IgG(Fc) Fab’2 coupled
to phycoerythrin (PE; Figure 4B). In a first step, the efficacy of
FIGURE 4 | Evaluation of homogenous BRET screening assay for
detection of scFv-Nluc binders on a directly (A) or indirectly labeled
target (B). BRET signal measurement of increasing amounts of specific
(squares) or aspecific (diamonds) Nluc fused scFv incubated either with a
Alexa-fluor488 covalently labeled target (A) or an indirectly labeled target-Fc
fusion with an (Fab’)2 anti-human Fc coupled to phycoerythrin (B). BRET
signal of specific scFv-Nluc incubated with an (Fab’)2 anti-human Fc coupled
to phycoerythrin in absence of target is represented with empty square.
Experimental points are means of triplicates of three independent
experiments, bars are SD.
BRET was tested with a reference anti-target 3 scFv-Nluc in dose
response to determine the range of scFv-Nluc expression level
allowing detection of positive hits. Anti-target 2 scFv-Nluc served
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FIGURE 5 | Screening of 92 scFv-Nluc derived from library L3 panned against target 3 using either ELISA on recombinant protein (A), on cells (B) or
the BRET assays with direct (C) or indirect (D) labeling of the target. For all graphs, the x-axis corresponds to the luminescence of a sample of scFv extract
before experiment indicating the relative quantity of each scFv. For cellular ELISA, results are the difference between the signal with CHO cells stably expressing
target 3 and the signal of untransfected CHO. The dotted lines correspond to the selected threshold for positive clones.
as a negative control. Figures 4A,B show a robust BRET signal
of 117.3 ± 10.6 and 156.3 ± 6.0 mBU, respectively, which was
stable over a wide range of luminescence (from 103 to 1.6 × 106
RLU). This was expected as BRET signal is ratiometric, the same
BRET signal will be obtained as long as the labeled antigen is
in excess and the quantity of unbound scFv-Nluc is low. Both
labeling procedures of the antigen were equally efficient with a
low unspecific signal of 9.2± 2.4 and 9.5± 1.3 mBU, respectively.
Moreover, a background BRET signal of 11.4 ± 2.5 mBU was
obtained with the positive control scFv-Nluc and the anti-
human IgG(Fc) Fab’2-PE in absence of target-Fc showing that no
unspecific energy transfer occurred due to a direct binding of the
labeled Fab’2 to scFv-Nluc. However, reading conditions under
1000 RLU resulted in significant increase of standard deviation
and should not be taken into account.
For proof-of-concept, library output cloned into the Nluc
vector pPL302 were produced and after expression level
evaluation by luminescence reading, crude extracts were
directly screened with BRET-based homogeneous assays using
direct and indirectly labeled antigen. Results obtained were
compared to those of recombinant protein or cellular ELISA.
Figure 5 represents the re-screening of 92 scFv-Nluc derived
from library L3 panned against target 3 using either ELISA
(Figures 5A,B) or the BRET assays (Figures 5C,D). For the
ELISA assays, plates were coated with recombinant target 3-
Fc-fusion protein or CHO cells stably over-expressing human
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target 3. Untransfected CHO served as a negative control.
For the BRET assays, target 3 covalently labeled with Alexa-
Fluor-488 or its Fc-fusion derivative labeled with Fab’2 anti-
IgG-Phycoerythrin was used. Amongst these 92 scFv-Nluc
products, 84 showed a sufficient expression level for accurate
screening. ELISA on recombinant target 3 and BRET assays
allowed the recovery of 27 positive clones while cellular
ELISA confirmed only 22 of them (Figures 5A,B). Four of
the five missing clones (B5, B7, B11, and B12) were not
taken into consideration due to higher signal on the control
CHO. The fifth clone (E5) already showed weak binding in
protein ELISA. It is also worth mentioning that in BRET assay
with Alexa-Fluor488 labeled target 3, an additional positive
hit was detected (G10) whereas in ELISA on recombinant
protein one additional weakly binding clone (H2) was included
in the list of positives. However, the overall similarity of
positive hits measured in ELISA and the homogeneous assays
demonstrates the robustness and flexibility of Nluc-fusion
protein screenings.
ScFv and IgG Nluc Fusion in Competition
ELISA
In case of affinity maturations, humanizations and epitope
mappings, competition assays are often used for screening
of variants which have superior or different characteristics
compared to the parental antibody. In order to test the
Nluc reporter system for such applications, a competition
assay has been set up with anti-target 2 mAb-Nluc fusion
for proof-of-concept. As shown in Figure 6 untagged anti
target 2 mAb prevented the binding of 1 nmol/L of its
Nluc-fusion in a dose-dependant fashion with an IC50 of
2.5 nmol/L while an irrelevant antibody showed no competition.
The untagged scFv format of the anti-target 2 mAb was
also able to compete with 1 nmol/L of the IgG Nluc-
fusion but with an IC50 of 16.2 nmol/L. This higher IC50
most likely reflects the avidity of the IgG compared to the
monovalent scFv.
ScFv and IgG Nluc Fusion for Western
Blotting
For a rapid screening of antibodies which can be used in Western
blotting, the Nluc reporter system was applied for detection of
recombinant targets 2 and 3 with specific antibodies. A band at
the expected size of 80 kDa was detected for recombinant target
2 when the antibody was used as IgG (Figure 7B, lane T2) or
scFv fused to Nluc (Figure 7C, lane T2) while no signal was
detected on recombinant target 3 Fc fusion (Figures 7B,C, lanes
T3). The same protein pattern was obtained with the untagged
anti-target 2 antibody and standard peroxidase-staining although
to a much weaker extent (Figure 7A, lane T2). One fainter
additional band at 37 kDa could be observed most likely due to
a degradation product of the recombinant target 2 protein. The
target 3-Fc fusion protein could be detected at 140 kDa with the
anti-target 3 Nluc-scFv. (Figure 7D, lane T3) An even higher
migrating band at >250 kDa is most likely due to a portion of
dimers.
FIGURE 6 | Binding competition ELISA on recombinant target 2
between a Nluc-fused anti-target 2 mAb (1 nmol/L) and specific
competitors [mAb (squares) and scFv (circles) or irrelevant antibodies
mAb (diamonds) and scFv (triangles)]. Each experimental point is the
mean of three independent experiments performed in triplicates, bars
correspond to SEM.
DISCUSSION
The high number of binders to evaluate after a phage panning
campaign requires efficient and fast methods of screening for
the properties desired of hits. Nluc by its robustness, its small
size and its bright luminescence activity showed that it could be
a flexible and powerful tool for high throughput screening of
panning outputs. We have shown that scFv fused Nluc allows
the reduction of experimental steps, a low background, a high
signal to noise and the possibility to establish homogenous
assay all of which are key points for HTS. The strong intensity
and the duration of the signal permit the detection of small
quantities of products and thus the miniaturization of the assay
volume, suitable for 384 and 1536 well plate format. We found
that the high intensity of the signal permitted reduced reading
times per well and that the long half-life of the signal opens
the possibility of stacking plates before reading. In our assay,
the scFv-Nluc were produced from only 120 µL of bacterial
culture, although this volume was still in vast excess compared to
the quantity actually needed to perform the individual analyses.
Comparison of the luminescence from mAbs fused to Nluc and
purified Nluc alone demonstrated that the fusion to a protein
did not interfere with Nluc activity. This property allows the
semi quantitative evaluation of scFv-Nluc expression levels an
important and typically inaccessible value required to validate
binding ELISA signals. It should be mentioned that while the
intensity of ELISA signal is proportional to the quantity of
bound Nluc fusion protein, this is not the case for BRET
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FIGURE 7 | Western blot of targets 2 and 3 revealed with naked anti target 2 mAb and an anti-human kappa light chain-HRP secondary antibody (A),
the Nluc fused to anti-target 2 antibody (B), the scFv-Nluc version of the anti-target 2 antibody (C) and an anti-target 3 scFv-Nluc (D). Membrane A
labeling was revealed with ECL blotting substrate, while membranes (B–D) labeling was revealed with furimazine diluted 1000 fold in PBS, 0.1% BSA.
signals. Indeed, as we have shown, the BRET signal was the
same for a wide range of quantities of a given scFv-Nluc as
long as the target labeled with the acceptor is not limiting.
Moreover two scFv-Nluc which bind with the same affinity to
the same target could give different BRET signals if they bind
to different epitopes due to spatial separation effects of donor
to acceptor. The distance between the energy donor (Nluc)
and the fluorescence acceptor should be less than 10 nm, for
energy transfer to occur; a labeling strategy that exceeds this
criterion will potentially create false negatives. The labeling
strategies already employed within this work demonstrate that
the margin for successful signal transfer is relatively large and
should be readily adaptable to the majority of situations. Thus
BRET technology allows the establishment of fast homogeneous
assays allowing a quick identification of binders but not an
affinity ranking, alternatively ELISA combined to the estimation
of scFv-Nluc concentration gives information of the relative
affinity between binders but requires additional experimental
steps.
We have shown, that the fusion of Nluc to antibodies or
scFv allows the establishment of various assays for screening
and characterization (Western blots, ELISA, BRET, and
competition assays). But the spectrum of assays that could
be developed is potentially even greater. For example,
functional competition assays to detect binders preventing
ligand/receptor interaction can be developed. The sensitivity
of BRET assays may also be improved through the use of
novel acceptors such as NanoBRET acceptor (Promega) that
has a broadly separated emission spectrum (Machleidt et al.,
2015).
The characterization of hits identified during the screening
process with Nluc offers several other opportunities. Several
authors have shown that Nluc luminescence can be easily
detected with a bioluminescence dedicated microscope (Hall
et al., 2012; Stacer et al., 2013), thus we can speculate that
Nluc fused antibodies could also find use as cell or tissue
labeling agents for cell microscopy or immunohistochemistry.
Furthermore, Stacer et al. (2013) described the use of
Nluc as a reporter for small animal in vivo imaging, Tran
et al. (2013) describing a similar approach with an Nluc
expressing Influenza reporter virus. Circulating levels of Nluc
fusions could easily be determined by regular sampling
of Nluc signal in serum samples, biodistribution could
in turn be followed via a small animal in vivo imaging
device. The emission spectra peak of 460 nm, results in
a strong attenuation of the signal in deep tissues (De
et al., 2009; Stacer et al., 2013) a problem that may be
surmountable by a shift of the light emitted toward the
red wavelength by generating a kind of BRET3 using
compatible mutant red fluorescent protein such as mOrange or
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the NanoBRET acceptor as proposed by De et al. (2009) with
the RLuc8 mutant of the Rluc. The robust enzymatic activity
of Nluc does decrease in acidic conditions (Hall et al., 2012).
Based on this property, we envisage its use to follow Ab-Nluc
or scFv-Nluc binding and internalization within cells through
the resultant pH dependant signal decrease, which will permit
the selection of candidates for antibody drug conjugate (ADC)
therapies.
In summary, the small size, high stability and signal
intensity of the luminescence, make Nluc a reporter of choice
when fused to whole antibodies or fragments to generate
multipotent tools essential for library screening, antibody
characterization and in vitro and in vivo assays generation. The
results demonstrate that Nluc is a versatile tool for screening
of scFv libraries and other antibody formats. It does not
interfere with solubility, binding or functionality and, showed
an unsurpassed sensitivity in different ELISA set ups, including
cell ELISA. The Nluc could be used for rapid quantification
of the fusion partner and hence for rapid affinity rankings
or affinity determinations by SET and finally could be used
in homogenous immunological assays for cost-effective high
throughput screens.
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